RFG Advisory’s Ligand Pharmaceuticals LGND Stock Holding History

RFG Advisory’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,544	Closed	-$508K	–	1164
2026 Q1	$508K	Buy	+2,544	New	+$503K	0.01%	736

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RFG Advisory's LGND Position: Q2 2026 in Review

RFG Advisory sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 2,544 shares — an estimated $508K sold.

RFG Advisory first reported a position in LGND in Q1 2026 and held it in 1 quarter. The position peaked at $508K in Q1 2026. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

RFG Advisory reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
RFG Advisory sold 2,544 Ligand Pharmaceuticals shares in Q2 2026, an estimated $508K.
RFG Advisory first reported a position in Ligand Pharmaceuticals in Q1 2026 and held it in 1 quarter.
RFG Advisory's Ligand Pharmaceuticals position peaked at $508K in Q1 2026.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on RFG Advisory's 13F filing for Q2 2026, filed 15 Jul 2026.